最佳氟达拉滨淋巴细胞清除暴露与CAR-T细胞治疗后结局改善相关
该回顾性分析纳入152例复发/难治B细胞急性淋巴细胞白血病患者,接受环磷酰胺/氟达拉滨淋巴细胞清除后输注替沙基奥仑赛,用经验证群体药代动力学模型估算氟达拉滨AUC。AUC≥13.8 mg×h/L为最佳暴露,低于此值者累积复发率更高、复发或B细胞再生障碍丧失风险更高。
要点
- 最佳氟达拉滨暴露定义为AUC≥13.8 mg×h/L。
- AUC<13.8 mg×h/L者累积复发率升高(HR 2.45)。
- AUC<13.8 mg×h/L者复发或B细胞再生障碍丧失风险升高(HR 1.96)。
核心结论
- 最佳氟达拉滨暴露与CAR-T治疗后结局改善相关;基于本分析,个体化药代动力学指导给药可能减少复发,但应在前瞻性试验中检验。
研究设计与样本
- 回顾性分析,纳入152例复发/难治B细胞急性淋巴细胞白血病患者,接受环磷酰胺/氟达拉滨淋巴细胞清除后输注替沙基奥仑赛。
- 使用经验证群体药代动力学模型估算氟达拉滨AUC(mg×h/L)。
主要发现
- 中位年龄12.5岁(范围<1至26岁),缓解率86%(131/152),12个月总生存率75.1%(95%CI 67.6%–82.6%),12个月累积复发率36.4%(95%CI 27.5%–45.2%)。
- 最佳氟达拉滨暴露为AUC≥13.8 mg×h/L。
- 多变量分析中,AUC<13.8 mg×h/L者较最佳暴露者累积复发率更高(HR 2.45;95%CI 1.34–4.48;P=.005),复发或B细胞再生障碍丧失风险更高(HR 1.96;95%CI 1.19–3.23;P=.01)。
- 高输注前疾病负荷与复发风险升高(HR 2.66;95%CI 1.45–4.87;P=.001)和死亡风险升高(HR 4.77;95%CI 2.10–10.9;P<.001)相关。
关键数值与推荐
- 最佳氟达拉滨暴露:AUC≥13.8 mg×h/L。
- AUC<13.8 mg×h/L者累积复发率HR 2.45(95%CI 1.34–4.48;P=.005)。
- AUC<13.8 mg×h/L者复发或B细胞再生障碍丧失风险HR 1.96(95%CI 1.19–3.23;P=.01)。
- 高输注前疾病负荷者复发风险HR 2.66(95%CI 1.45–4.87;P=.001),死亡风险HR 4.77(95%CI 2.10–10.9;P<.001)。
临床怎么用
- 作者认为,个体化药代动力学指导给药以达到最佳氟达拉滨暴露应在前瞻性试验中检验,并可能减少CAR-T治疗后的疾病复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improves immune reconstitution, resulting in lower nonrelapse mortality and increased survival. We hypothesized that optimal fludarabine exposure in lymphodepleting chemotherapy before CAR T-cell therapy would improve outcomes. In a retrospective analysis of patients with relapsed/refractory B-cell acute lymphoblastic leukemia undergoing CAR T-cell (tisagenlecleucel) infusion after cyclophosphamide/fludarabine lymphodepleting chemotherapy, we estimated fludarabine exposure as area under the curve (AUC; mg × h/L) using a validated population pharmacokinetic (PK) model. Fludarabine exposure was related to overall survival (OS), cumulative incidence of relapse (CIR), and a composite end point (loss of B-cell aplasia [BCA] or relapse). Eligible patients (n = 152) had a median age of 12.5 years (range, <1 to 26), response rate of 86% (n = 131 of 152), 12-month OS of 75.1% (95% confidence interval [CI], 67.6% to 82.6%), and 12-month CIR of 36.4% (95% CI, 27.5% to 45.2%). Optimal fludarabine exposure was determined as AUC ≥13.8 mg × h/L. In multivariable analyses, patients with AUC <13.8 mg × h/L had a 2.5-fold higher CIR (hazard ratio [HR], 2.45; 95% CI, 1.34-4.48; P = .005) and twofold higher risk of relapse or loss of BCA (HR, 1.96; 95% CI, 1.19-3.23; P = .01) compared with those with optimal fludarabine exposure. High preinfusion disease burden was also associated with increased risk of relapse (HR, 2.66; 95% CI, 1.45-4.87; P = .001) and death (HR, 4.77; 95% CI, 2.10-10.9; P < .001). Personalized PK-directed dosing to achieve optimal fludarabine exposure should be tested in prospective trials and, based on this analysis, may reduce disease relapse after CAR T-cell therapy.
引用
- Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022. PMID: 34788386. doi:10.1182/bloodadvances.2021006418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。